261 related articles for article (PubMed ID: 14699048)
1. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Braun BS; Tuveson DA; Kong N; Le DT; Kogan SC; Rozmus J; Le Beau MM; Jacks TE; Shannon KM
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):597-602. PubMed ID: 14699048
[TBL] [Abstract][Full Text] [Related]
2. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.
Chan IT; Kutok JL; Williams IR; Cohen S; Kelly L; Shigematsu H; Johnson L; Akashi K; Tuveson DA; Jacks T; Gilliland DG
J Clin Invest; 2004 Feb; 113(4):528-38. PubMed ID: 14966562
[TBL] [Abstract][Full Text] [Related]
3. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
[TBL] [Abstract][Full Text] [Related]
4. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
[TBL] [Abstract][Full Text] [Related]
5. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
[TBL] [Abstract][Full Text] [Related]
6. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia.
Chan IT; Gilliland DG
Cell Cycle; 2004 May; 3(5):536-7. PubMed ID: 15020845
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
[TBL] [Abstract][Full Text] [Related]
9. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
Van Meter ME; Díaz-Flores E; Archard JA; Passegué E; Irish JM; Kotecha N; Nolan GP; Shannon K; Braun BS
Blood; 2007 May; 109(9):3945-52. PubMed ID: 17192389
[TBL] [Abstract][Full Text] [Related]
10. Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.
Wang J; Liu Y; Tan LX; Lo JC; Du J; Ryu MJ; Ranheim EA; Zhang J
Cell Cycle; 2011 Sep; 10(17):2836-9. PubMed ID: 21857161
[TBL] [Abstract][Full Text] [Related]
11. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.
Le DT; Kong N; Zhu Y; Lauchle JO; Aiyigari A; Braun BS; Wang E; Kogan SC; Le Beau MM; Parada L; Shannon KM
Blood; 2004 Jun; 103(11):4243-50. PubMed ID: 14982883
[TBL] [Abstract][Full Text] [Related]
12. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
[TBL] [Abstract][Full Text] [Related]
13. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
[TBL] [Abstract][Full Text] [Related]
14. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.
Braun BS; Archard JA; Van Ziffle JA; Tuveson DA; Jacks TE; Shannon K
Blood; 2006 Sep; 108(6):2041-4. PubMed ID: 16720837
[TBL] [Abstract][Full Text] [Related]
15. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease.
Wahlstrom AM; Cutts BA; Karlsson C; Andersson KM; Liu M; Sjogren AK; Swolin B; Young SG; Bergo MO
Blood; 2007 Jan; 109(2):763-8. PubMed ID: 16973961
[TBL] [Abstract][Full Text] [Related]
16. Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia.
Baker SJ; Cosenza SC; Ramana Reddy MV; Premkumar Reddy E
Oncotarget; 2019 Mar; 10(20):1932-1942. PubMed ID: 30956775
[TBL] [Abstract][Full Text] [Related]
17. Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.
Munugalavadla V; Sims EC; Chan RJ; Lenz SD; Kapur R
Exp Hematol; 2008 Mar; 36(3):301-8. PubMed ID: 18179858
[TBL] [Abstract][Full Text] [Related]
18. Mouse model for NRAS-induced leukemogenesis.
Parikh C; Ren R
Methods Enzymol; 2008; 439():15-24. PubMed ID: 18374153
[TBL] [Abstract][Full Text] [Related]
19. Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras.
Guo X; Schrader KA; Xu Y; Schrader JW
Oncogene; 2005 Mar; 24(14):2330-42. PubMed ID: 15735740
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic transforming potential of activated ras in chimeric mice.
Hawley RG; Fong AZ; Ngan BY; Hawley TS
Oncogene; 1995 Sep; 11(6):1113-23. PubMed ID: 7566971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
